An overview of micafungin as a treatment option for invasive candidiasis in pediatric patients younger than 4 months old

References

• Barton M, O’Brien K, Robinson JL, et al. Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infect Dis. 2014 Jun 12;14(1):327.
   PubMedGoogle Scholar
• Benjamin DK Jr., Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006 Jan;117(1):84–92.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018 May 11;4(1):18026.
   PubMedGoogle Scholar
• Kilpatrick R, Scarrow E, Hornik C, et al. Neonatal invasive candidiasis: updates on clinical management and prevention. Lancet Child Adolesc Health. 2022 Jan;6(1):60–70.
   PubMedGoogle Scholar
• Abdel-Haq N, Smith SM, Asmar BI. Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age. Expert Rev Anti Infect Ther. 2022 Apr;20(4):493–505.
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr., Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010 Oct;126(4):e865–73.
   PubMed Web of Science ®Google Scholar
• Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006 Aug;118(2):717–722.
   PubMed Web of Science ®Google Scholar
• Lee JH, Hornik CP, Benjamin DK Jr., et al. Risk factors for invasive candidiasis in infants >1500 g birth weight. Pediatr Infect Dis J. 2013 Mar;32(3):222–226.
   PubMed Web of Science ®Google Scholar
• Aliaga S, Clark RH, Laughon M, et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics. 2014 Feb;133(2):236–242.
   PubMed Web of Science ®Google Scholar
• Mantadakis E, Pana ZD, Zaoutis T. Candidemia in children: epidemiology, prevention and management. Mycoses. 2018 Sep;61(9):614–622.
   PubMed Web of Science ®Google Scholar
• Pana ZD, Roilides E, Warris A, et al. Epidemiology of invasive fungal disease in children. J Pediatric Infect Dis Soc. 2017 Sep 1;6(suppl_1):S3–S11.
   PubMedGoogle Scholar
• Walsh TJ, Katragkou A, Chen T, et al. Invasive candidiasis in infants and children: recent advances in epidemiology, diagnosis, and treatment. J Fungi. 2019 Jan 24;5(1):11.
   Web of Science ®Google Scholar
• Hashimoto S. Micafungin: a sulfated echinocandin. J Antibiot (Tokyo). 2009 Jan;62(1):27–35.
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Fujie A, Sakamoto K, et al. WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo). 1994 Oct;47(10):1084–1091.
   PubMed Web of Science ®Google Scholar
• Nyfeler R, Keller-Schierlein W, Nüesch J. [Stoffwechselprodukte von Mikroorganismen 143. Mitteilung. Echinocandin B, ein neuartiges Polypeptid-Antibioticum aus Aspergillus nidulans var. echinulatus: isolierung und Bausteine]. Helv Chim Acta. 1974;57(8):2459–2477.
   PubMed Web of Science ®Google Scholar
• Schwartz RE, Giacobbe RA, Bland JA, et al. L-671,329, a new antifungal agent. I. Fermentation and isolation. J Antibiot (Tokyo). 1989 Feb;42(2):163–167.
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet. 2003 Oct 4;362(9390):1142–1151.
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol. 1997 Mar-Apr;35(2):79–86.
   PubMedGoogle Scholar
• Giacobbe DR, Del Bono V, Viscoli C, et al. Use of 1,3-beta-D-glucan in invasive fungal diseases in hematology patients. Expert Rev Anti Infect Ther. 2017 Dec;15(12):1101–1112.
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Paetznick VL, Rodriguez JR, et al. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol. 2006 May;44(3):267–272.
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc. 2002;51(4):247–255.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Mycamine (R). Summary of product characteristics last accessed 12 Jun 2022]. Available at 2022 Jun 12: https://www.ema.europa.eu/en/documents/product-information/mycamine-epar-product-information_en.pdf.
   Google Scholar
• Taormina G, Gopinath R, Moore J, et al. A regulatory review approach for evaluation of micafungin for treatment of neonatal candidiasis. Clin Infect Dis. 2021 Dec 16;73(12):2335–2340.
   PubMed Web of Science ®Google Scholar
• Tezer H, Canpolat FE, Dilmen U. Invasive fungal infections during the neonatal period: diagnosis, treatment and prophylaxis. Expert Opin Pharmacother. 2012 Feb;13(2):193–205.
   PubMed Web of Science ®Google Scholar
• Bersani I, Piersigilli F, Goffredo BM, et al. Antifungal Drugs for Invasive Candida Infections (ICI) in neonates: future perspectives. Front Pediatr. 2019;7:375.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Smith PB, Benjamin DK Jr., et al. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos. 2011 May;32(4):222–232.
   PubMed Web of Science ®Google Scholar
• Wasmann RE, Muilwijk EW, Burger DM, et al. Clinical pharmacokinetics and pharmacodynamics of micafungin. Clin Pharmacokinet. 2018 Mar;57(3):267–286.
   PubMed Web of Science ®Google Scholar
• Auriti C, Falcone M, Ronchetti MP, et al. High-dose micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. Antimicrob Agents Chemother. 2016 Dec;60(12):7333–7339.
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr., Kaufman DA, Hope WW, et al. A phase 3 study of micafungin versus amphotericin b deoxycholate in infants with invasive candidiasis. Pediatr Infect Dis J. 2018 Oct;37(10):992–998.
   PubMed Web of Science ®Google Scholar
• Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008 Jan 1;197(1):163–171.
   PubMed Web of Science ®Google Scholar
• Leroux S, Jacqz-Aigrain E, Elie V, et al. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. Br J Clin Pharmacol. 2018 Sep;84(9):1989–1999.
   PubMed Web of Science ®Google Scholar
• Emiroglu M. Micafungin use in children. Expert Rev Anti Infect Ther. 2011 Sep;9(9):821–834.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lewis JS. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155–1166.
   PubMed Web of Science ®Google Scholar
• Fromtling RA. Micafungin sodium (FK-463). Drugs Today (Barc). 2002 Apr;38(4):245–257.
   PubMed Web of Science ®Google Scholar
• Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006 Dec;25(12):1110–1115.
   PubMed Web of Science ®Google Scholar
• Auriti C, Goffredo BM, Ronchetti MP, et al. High-dose micafungin in neonates and young infants with invasive candidiasis: results of a phase 2 study. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02494–20.
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007 May 5;369(9572):1519–1527.
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008 Sep;27(9):820–826.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Bassetti M, Castagnola E, et al. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infect Dis. 2014 Dec 31;14(1):725.
   PubMedGoogle Scholar
• Schuller SS, Bauer C, Unterasinger L, et al. Safety and efficacy of micafungin in extremely low birth weight infants. Pediatr Infect Dis J. 2018 Jun;37(6):e169–e172.
   PubMed Web of Science ®Google Scholar
• Maede Y, Ibara S, Nagasaki H, et al. Micafungin versus fluconazole for prophylaxis against fungal infections in premature infants. Pediatr Int. 2013 Dec;55(6):727–730.
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004 Nov 15;39(10):1407–1416.
   PubMed Web of Science ®Google Scholar
• Kim BK, Choi JY, Hong KT, et al. Prospective study on prophylactic micafungin sodium against invasive fungal disease during neutropenia in pediatric & adolescent patients undergoing autologous hematopoietic stem cell transplantation. Children (Basel). 2022 Mar 7;9(3). DOI:10.3390/children9030372
   Web of Science ®Google Scholar
• El Cheikh J, Ceballos P, Dalle JH, et al. Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: a prospective, observational study in France. Diagn Microbiol Infect Dis. 2019 Jul;94(3):268–273.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Mycamine (R). Highlights of prescribing information last accessed 1 Jul 2022]. Available at 2022 Jul 1: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021506s023lbl.pdf.
   Google Scholar
• Benjamin DK Jr., Poole C, Steinbach WJ, et al. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics. 2003 Sep;112(3 Pt 1):634–640.
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Heydon K, Localio R, et al. Outcomes attributable to neonatal candidiasis. Clin Infect Dis. 2007 May 1;44(9):1187–1193.
   PubMed Web of Science ®Google Scholar
• Andes D. Regulatory level of evidence and practicality in antifungal use decisions for less common fungal diseases. Clin Infect Dis. 2021 Dec 16;73(12):2341–2343.
   PubMed Web of Science ®Google Scholar
• Ascher SB, Smith PB, Watt K, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J. 2012 May;31(5):439–443.
   PubMed Web of Science ®Google Scholar
• Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J. 1996 Dec;15(12):1107–1112.
   PubMed Web of Science ®Google Scholar
• Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003 Oct;52(4):663–667.
   PubMed Web of Science ®Google Scholar
• NDA multi-disciplinary review and evaluation NDA 21506/S-023: mycamine (micafungin sodium), 2019 last accessed 1 Jul 2022]. Available at 2022 Jul 1: https://www.fda.gov/media/134936/download.
   Google Scholar
• Borman AM, Szekely A, Johnson EM. Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. Med Mycol. 2017 Jul 1;55(5):563–567.
   PubMed Web of Science ®Google Scholar
• Briano F, Magnasco L, Sepulcri C, et al. Candida auris Candidemia in Critically Ill, Colonized Patients: cumulative Incidence and Risk Factors. Infect Dis Ther. 2022 Jun;11(3):1149–1160.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Sood P, Rudramurthy SM, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015 Feb;41(2):285–295.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Anil Kumar V, Sharma C, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):919–926.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017 May;13(5):e1006290.
   PubMed Web of Science ®Google Scholar
• Di Pilato V, Codda G, Ball L, et al. Molecular epidemiological investigation of a nosocomial cluster of C. auris: evidence of recent emergence in Italy and ease of transmission during the COVID-19 pandemic. J Fungi. 2021 Feb 15;7(2):140.
   Web of Science ®Google Scholar
• Lone SA, Ahmad A. Candida auris-the growing menace to global health. Mycoses. 2019 Aug;62(8):620–637.
   PubMed Web of Science ®Google Scholar
• Mesini A, Saffioti C, Mariani M, et al. First case of candida auris colonization in a preterm, extremely low-birth-weight newborn after vaginal delivery. J Fungi. 2021 Aug 10;7(8):649.
   Web of Science ®Google Scholar
• Osei Sekyere J. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen. 2018 Aug;7(4):e00578.
   PubMed Web of Science ®Google Scholar
• Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015 Dec 1;6(Suppl 6):S612–7.
   Google Scholar
• Al-Baqsami ZF, Ahmad S, Khan Z. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait. Sci Rep. 2020 Apr 10;10(1):6238.
   PubMed Web of Science ®Google Scholar
• Sharma D, Paul RA, Rudramurthy SM, et al. Impact of FKS1 genotype on echinocandin in vitro susceptibility in candida auris and in vivo response in a murine model of infection. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0165221.
   PubMed Web of Science ®Google Scholar
• Kordalewska M, Lee A, Park S, et al. Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob Agents Chemother. 2018 May 25;62(6):e00238–18.
   PubMed Web of Science ®Google Scholar
• Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core recommendations for antifungal stewardship: a statement of the mycoses study group education and research consortium. J Infect Dis. 2020 Aug 5;222(Suppl 3):S175–S198.
   PubMedGoogle Scholar